Cover Image
市場調查報告書

血管新生青光眼:全球臨床實驗檢討 (2015年前半期)

Neovascular Glaucoma Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 324944
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
血管新生青光眼:全球臨床實驗檢討 (2015年前半期) Neovascular Glaucoma Global Clinical Trials Review, H2, 2016
出版日期: 2016年11月30日 內容資訊: 英文 50 Pages
簡介

本報告提供血管新生青光眼相關之臨床研究最新趨勢調查,提供您地區·進展·PHASE·募集情況別之實驗量,代表性贊助商,開發中的治療藥資訊,並彙整全球各國的主要企業·機關的進展狀況,及有潛力的藥劑比較等資訊。

簡介

  • 血管新生青光眼
  • 報告指南

各地區的臨床實驗數量

  • 各國臨床實驗數量及平均參加者數
    • 亞太地區主要國家的臨床實驗數量
    • 歐洲主要國家的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要國家的臨床實驗數量
    • 中南美主要國家的臨床實驗數量

G7各國臨床實驗數量:眼科臨床實驗中血管新生青光眼的比例

G7各國臨床實驗數量:Phase別

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:眼科臨床實驗中血管新生青光眼的比例

E7各國臨床實驗數量:Phase別

E7各國臨床實驗數量:各進展狀況

Phase別臨床實驗數量

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

未完成的臨床實驗數量:血管新生青光眼

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

  • 血管新生青光眼的治療藥臨床實驗的主要參與企業

有潛力的藥劑

臨床實驗簡介

  • 代表性企業臨床實驗概況
    • Gene Signal International SA
    • ODIN Biotech Partners, LLC
  • 主要的研究機關/政府機關/醫院臨床實驗概要
    • 熊本大學
    • Federal University of Sao Paulo
    • University of Illinois
    • 島根大學
    • Universidade Federal de Uberlandia
    • Hong Kong Eye Hospital
    • University of Lubeck
    • Faculty of Medicine Siriraj Hospital, Mahidol University
    • Shahid Beheshti University of Medical Sciences
    • Cairo University

5個有代表性的臨床實驗簡介

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3972CTIDB

GlobalData's clinical trial report, "Neovascular Glaucoma Global Clinical Trials Review, H2, 2016" provides an overview of Neovascular Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Neovascular Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • Clinical Trials by Trial Status 21
  • Clinical Trials by End Point Status 22
  • Subjects Recruited Over a Period of Time 23
  • Clinical Trials by Sponsor Type 24
  • Prominent Sponsors 25
  • Top Companies Participating in Neovascular Glaucoma Therapeutics Clinical Trials 26
  • Prominent Drugs 27
  • Clinical Trial Profile Snapshots 28

Appendix 47

  • Abbreviations 47
  • Definitions 47
  • Research Methodology 48
  • Secondary Research 48
  • About GlobalData 49
  • Contact Us 49
  • Disclaimer 49
  • Source 50

List of Tables

List of Tables

  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Neovascular Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9
  • Neovascular Glaucoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Neovascular Glaucoma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Neovascular Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
  • Neovascular Glaucoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
  • Neovascular Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 24
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27

List of Figures

List of Figures

  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Neovascular Glaucoma Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9
  • Neovascular Glaucoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Neovascular Glaucoma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Neovascular Glaucoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, G7 Countries (%), 2016* 14
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Neovascular Glaucoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Neovascular Glaucoma to Ophthalmology Clinical Trials, E7 Countries (%), 2016* 17
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Neovascular Glaucoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
  • Neovascular Glaucoma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 21
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 22
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 23
  • Neovascular Glaucoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 24
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 25
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 26
  • Neovascular Glaucoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 27
  • GlobalData Methodology 48
Back to Top